OGEN - Oragenics begins toxicology study in animals to test intranasal COVID-19 vaccine candidate

Oragenics (NYSE:OGEN) starts toxicology study in rabbits to evaluate the safety profile and immunogenicity of its intranasal COVID-19 vaccine candidate, NT-CoV2-1 The company said the study is designed to provide Investigational New Drug (IND) data to help advance its candidate to human clinical studies. Oragenics, which has a contract with Frontage Laboratories through its unit Experimur to conduct the study, expects to report top-line interim data in August. Shares (OGEN +0.1%)

For further details see:

Oragenics begins toxicology study in animals to test intranasal COVID-19 vaccine candidate